Vaxart Inc
Gesloten
0
Overzicht
Wijziging aandelenprijs
24u
Min
Max
Inkomsten | -50M 5.2M |
|---|---|
Verkoop | -65M 39M |
K/W Sectorgemiddelde | 4.063 51.415 |
EPS | 0.02 |
Winstmarge | 13.203 |
Werknemers | 65 |
EBITDA | -53M 5.2M |
Volgende Winsten | 12 aug 2026 |
|---|
Marktkapitalisatie | -27M 157M |
|---|---|
Vorige openingsprijs | 0 |
Vorige sluitingsprijs | 0 |
Technische score
By Trading Central
Vertrouwen
Bearish Evidence
Vaxart Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Vaxart Inc Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
